Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activated receptor

Journal of the National Cancer Institute

Volumn 90, Issue 22, 1998, Pages 1702-1709

  Gonzalez, Frank J ^a,c   Peters, Jeffrey M ^a   Cattley, Russell C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CARCINOGEN; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIRINIXIC ACID; PLASTICIZER; TRICHLOROETHYLENE;

ARTICLE; CELL CYCLE; DRUG MECHANISM; GENE EXPRESSION; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; MITOGENESIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECIES DIFFERENCE;

EID: 0032545018     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.22.1702     Document Type: Article

References (77)

1. Tomatis L, Aitio A, Wilbourn J, Shuker L. Human carcinogens so far identified. Jpn J Cancer Res 1989;80: 795-807.
2. Butterworth BE, Conolly RB, Morgan KT. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments. Cancer Lett 1995; 93:129-46.
3. Ashby J, Brady A, Elcombe CR, Elliott BM, Ishmael J, Odum J, et al. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol 1994;13 Suppl 2:S1-117.
4. Reddy JK, Rao MS. Peroxisome proliferation and hepatocarcinogenesis. IARC Sci Publ 1992;225-35.
5. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
6. Oliver MF. Strategy of reducing coronary risk and the use of drugs. J Cardiovasc Pharmacol 1984;6 Suppl 6:S880-S887.
7. IARC monographs on the evaluation of carcinogenic risks to humans. IARC Sci Publ 1996;66:1-514.
8. Elcombe CR, Bell DR, Elias E, Hasmall SC, Plant NJ. Peroxisome proliferators: species differences in response of primary hepatocyte cultures. Ann N Y Acad Sci 1996;804:628-35.
9. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake B, Marsman D, et al. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol 1998;27(1 Pt 1):47-60.
10. Mannaerts GP, Van Veldhoven PP. Metabolic pathways in mammalian peroxisomes. Biochimie 1993;75:147-58.
11. Reddy JK, Chu R. Peroxisome proliferator-induced pleiotropic responses: pursuit of a phenomenon. Ann N Y Acad Sci 1996;804:176-201.
12. Green S, Wahli W. Peroxisome proliferator-activated receptors: finding the orphan a home. Mol Cell Endocrinol 1994;100:149-53.
13. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997;8:159-66.
14. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012-22.
15. Lemberger T, Braissant O, Juge-Aubry C, Keller H, Saladin R, Staels B, et al. PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann N Y Acad Sci 1996;804:231-51.
16. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996;87:377-89.
17. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-6.
18. Auwerx J, Schoonjans K, Fruchart JC, Staels B. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb 1996;3:81-9.
19. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, et al. Altered constitutive expression of fatty acid-melabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 1998;273:5678-84.
20. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 1997;272:27307-12.
21. Ren B, Thelen AP, Peters JM, Gonzalez FJ, Jump DB. Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha. J Biol Chem 1997;272:26827-32.
22. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997;272:28210-7.
23. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996;384:39-43.
24. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995;270:23975-83.
25. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxidase proliferator-activated receptor alpha and gamma activators in a tissue-and inducer-specific manner. J Biol Chem 1998;273:16710-4.
26. Reddy JK, Azarnoff DL, Hignite CE. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980;283: 397-8.
27. Lake BG. Peroxisome proliferation: current mechanisms relating to nongenotoxic carcinogenesis. Toxicol Lett 1995;82-83:673-81.
28. Marsman DS, Swanson-Pfeiffer CL, Popp JA. Lack of comitogenicity by the peroxisome proliferator hepatocarcinogens. Wy-14,643 and clofibric acid. Toxicol Appl Pharmacol 1993;122:1-6.
29. Carcinogenesis bioassay of di(2-ethylhexyl)phthalate (CAS No. 117-81-7) in F344 rats and B6C3F1 mice (feed study). US DHHS Technical Report Series No. 217. NTP(National Toxicology Program) 1982: 1-127.
30. Carcinogenesis studies of trichloroethylene (without epichlorohydrin) (CAS No. 79-01-6) in F344/n rats and B6C3F1 mice (gavage studies). US DHHS Technical Report Series No. 243. NTP (National Toxicology Program) 1990;1-174.
31. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997;18:2029-33.
32. Reddy JK, Rao MS. Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesis. Mutat Res 1989;214: 63-8.
33. Conway JG, Tomaszewski KE, Olson MJ, Cattley RC, Marsman DS, Popp JA. Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643. Carcinogenesis 1989;10:513-9.
34. Marsman DS, Goldsworthy TL, Popp JA. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid. Carcinogenesis 1992;13: 1011-7.
35. Conway JG, Popp JA. Effect of the hepatocarcinogenic peroxisome proliferator Wy-14,643 in vivo: no increase in ethane exhalation or hepatic conjugated dienes. Toxicol Appl Pharmacol 1995;135:229-36.
36. Soliman MS, Cunningham ML, Morrow JD, Roberts LJ, Badr MZ. Evidence against peroxisome proliferation-induced hepatic oxidative damage. Biochem Pharmacol 1997;53:1369-74.
37. Kasai H, Okada Y, Nishimura S, Rao MS, Reddy JK. Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator. Cancer Res 1989;49:2603-5.
38. Takagi A, Sai K, Umemura T, Hasegawa R, Kurokawa Y. Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators: di(2-ethylhexyl) phthalate, aluminium clofibrate and simfibrate. Cancer Lett 1990;53:33-8.
39. Cattley RC, Glover SE. Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: relationship to carcinogenesis and nuclear localization. Carcinogenesis 1993;14:2495-9.
40. Hegi ME, Ulrich D, Sagelsdorff P, Richter C, Lutz WK. No measurable increase in thymidine glycol or 8-hydroxydeoxyguanosine in liver DNA of rats treated with nafenopin or choline-devoid low-methionine diet. Mutat Res 1990;238:325-9.
41. 2-generating peroxisomal fatty acyl-CoA oxidase. Proc Natl Acad Sci U S A 1995;92:7080-4.
42. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors m mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 1998;273:15639-45.
43. Jones HB, Eldridge SR, Butterworth BE, Foster JR. Measures of cell replication in risk/safety assessment of xenobiotic-induced, nongenotoxic carcinogenesis. Regul Toxicol Pharmacol 1996;23:117-27.
44. Marsman DS, Cattley RC, Conway JG, Popp JA. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res 1988;48:6739-44.
45. Ma X, Stoffregen DA, Wheelock GD, Rininger JA, Babish JG. Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21Waf1 cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) dosing to rats. Mol Pharmacol 1997;51:69-78.
46. Peters JM, Aoyama T, Cattley RC, Usuda M, Hashimoto T, Gonzalez FJ. Role of peroxisome proliferator-activated receptor-α in altered cell cycle regulation in mouse liver. Carcinogenesis 1998;19:1989-94.
47. Roberts RA. Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. AnnNYAcadSci 1996;804:588-611.
48. Roberts RA, Nebert DW, Hickman JA, Richburg JH, Goldsworthy TL. Perturbation of the mitosis/apoptosis balance: a fundamental mechanism in toxicology. Fundam Appl Toxicol 1997;38:107-15.
49. Roberts RA, Soames AR, Gill JH, James NH, Wheeldon EB. Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. Carcinogenesis 1995;16:1693-8.
50. Strange J, Roberts RA. Reduced expression of mature TGF beta 1 correlates with the suppression of rat hepatocyte apoptosis by the peroxisome proliferator, nafenopin. Mutat Res 1996;372:107-13.
51. James NH, Roberts RA. Species differences in the clonal expansion of hepatocytes in response to the coaction of epidermal growth factor and nafenopin, a rodent hepatocarcinogenic peroxisome proliferator. Fundam Appl Toxicol 1995;26:143-9.
52. Roberts RA, James NH, Woodyatt NJ, Macdonald N, Tugwood JD. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPARα). Carcinogenesis 1998;19:43-8.
53. Conway JG, Cattley RC, Popp JA, Butterworth BE. Possible mechanisms in hepatocarcinogenesis by the peroxisome proliferator di(2-ethylhexyl)phthalate. Drug Metab Rev 1989;21:65-102.
54. Reddy JK, Reddy MK, Usman MI, Lalwani ND, Rao MS. Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl) adipate with a hypolipidemic drug. Environ Health Perspect 1986;65:317-27.
55. Tomaszewski KE, Agarwal DK, Melnick RL. In vitro steady-state levels of hydrogen peroxide after exposure of male F344 rats and female B6C3F1 mice to hepatic peroxisome proliferators. Carcinogenesis 1986;7:1871-6.
56. Grasl-Kraupp B, Huber W, Timmermann-Trosiener I, Schulte-Hermann R. Peroxisomal enzyme induction uncoupled from enhanced DNA synthesis in putative preneoplastic liver foci of rats treated with a single dose of the peroxisome proliferator nafenopin. Carcinogenesis 1993;14:2435-7.
57. Bojes HK, Thurman RG. Peroxisome proliferators activate Kupffer cells in vivo. Cancer Res 1996;56:1-4.
58. Rose ML, Germolec DR, Schoonhoven R, Thurman RG. Kupffer cells are causally responsible for the mitogenic effect of peroxisome proliferators. Carcinogenesis 1997;18:1453-6.
59. Mikalsen SO, Kaalhus O, Reith A, Sanner T. Role of catalase and oxidative stress in hepatic peroxisome proliferator-induced morphological transformation of Syrian hamster embryo cells. Int J Cancer 1990;46:950-7.
60. Tsutsui T, Watanabe E, Barren JC. Ability of peroxisome proliferators to induce cell transformation, chromosome aberrations and peroxisome proliferation in cultured Syrian hamster embryo cells. Carcinogenesis 1993; 14:611-8.
61. Miller RT, Glover SE, Stewart WS, Corton JC, Popp JA, Cattley RC. Effect on the expression of c-met, c-myc and PPAR-alpha in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator WY-14,643. Carcinogenesis 1996;17:1337-41.
62. Cunningham ML, Soliman MS, Badr MZ, Matthews HB. Rotenone, an anticarcinogen, inhibits cellular proliferation but not peroxisome proliferation in mouse liver. Cancer Lett 1995;95:93-7.
63. NTP (1988) National Toxicology Program Technical Report No. 320. Toxicology and Carcinogenesis studies in F344/N and B6C3F1 mice (feed studies). NIH Publ No. 88-2576, National Technical Information Service (NITS), 1988.
64. Rininger JA, Wheelock GD, Ma X, Babish JG. Discordant expression of the cyclin-dependent kinases and cyclins in rat liver following acute administration of the hepatocarcinogen [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY14,643). Biochem Pharmacol 1996;52: 1749-55.
65. Rininger JA, Goldsworthy TL, Babish JG. Time course comparison of cell-cycle protein expression following partial hepatectomy and WY14,643-induced hepatic cell proliferation in F344 rats. Carcinogenesis 1997;18:935-41.
66. Motoki Y, Tamura H, Morita R, Watanabe T, Suga T. Decreased hepatocyte growth factor level by Wy-14,643, non-genotoxic hepatocarcinogen in F-344 rats. Carcinogenesis 1997;18:1303-9.
67. Popp JA, Cattley RC. Peroxisome proliferators as initiators and promoters of rodent hepatocarcinogenesis. In: Gibson G, Lake B, editors. Monograph on peroxisome proliferation. London: Taylor & Francis; 1993. p. 653-65.
68. Marsman DS, Popp JA. Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy14,643. Carcinogenesis 1994;15:111-7.
69. Grasl-Kraupp B, Ruttkay-Nedecky B, Mullauer L, Taper H, Huber W, Bursch W, et al. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology 1997;25:906-12.
70. Lake BG, Evans JG, Gray TJ, Korosi SA, North CJ. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat. Syrian hamster, guinea pig, and marmoset. Toxicol Appl Pharmacol 1989;99: 148-60.
71. Reddy JK, Lalwani ND, Qureshi SA, Reddy MK, Moehle CM. Induction of hepatic peroxisome proliferation in nonrodent species, including primates. Am J Pathol 1984;114:171-83.
72. Lalwani ND, Reddy MK, Ghosh S, Barnard SD, Molello JA, Reddy JK. Induction of fatty acid beta-oxidation and peroxisome proliferation in the liver of rhesus monkeys by DL-040, a new hypolipidemic agent. Biochem Pharmacol 1985;34:3473-82.
73. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993;32:5598-604.
74. Mukherjee R, Jow L, Noonan D, McDonnell DP. Human and rat peroxisome proliferator-activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 1994;51:157-66.
75. Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ. Peroxisome proliferator-activated receptors: structures and function. Ann N Y Acad Sci 1996;804:252-65.
76. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferation activated receptor-alpha expression in human liver. Mol Pharmacol 1998;53:14-22.
77. Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 1996;271:2147-55.